Literature DB >> 10066645

Immunological features of Pneumocystis carinii infection in humans.

P D Walzer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10066645      PMCID： PMC95678          DOI： 10.1128/CDLI.6.2.149-155.1999

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN： 1071-412X


× No keyword cloud information.
  134 in total

1.  The carbohydrate recognition domain of surfactant protein A mediates binding to the major surface glycoprotein of Pneumocystis carinii.

Authors:  F X McCormack; A L Festa; R P Andrews; M Linke; P D Walzer
Journal:  Biochemistry       Date:  1997-07-01       Impact factor: 3.162

2.  Human immunodeficiency virus type 1 infection of human macrophages modulates the cytokine response to Pneumocystis carinii.

Authors:  O Kandil; J A Fishman; H Koziel; P Pinkston; R M Rose; H G Remold
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

3.  Immunization with the major surface glycoprotein of Pneumocystis carinii elicits a protective response.

Authors:  S A Theus; A G Smulian; P Steele; M J Linke; P D Walzer
Journal:  Vaccine       Date:  1998-07       Impact factor: 3.641

4.  Phenotypic analysis of bronchoalveolar lavage lymphocytes from acquired immunodeficiency patients with and without Pneumocystis carinii pneumonia.

Authors:  J Guzman; Y M Wang; H Teschler; K Kienast; N Brockmeyer; U Costabel
Journal:  Acta Cytol       Date:  1992 Nov-Dec       Impact factor: 2.319

5.  Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children.

Authors:  L L Pifer; W T Hughes; S Stagno; D Woods
Journal:  Pediatrics       Date:  1978-01       Impact factor: 7.124

6.  Adoptive transfer of lymphocytes sensitized to the major surface glycoprotein of Pneumocystis carinii confers protection in the rat.

Authors:  S A Theus; R P Andrews; P Steele; P D Walzer
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

7.  Immunization with Pneumocystis carinii gpA is immunogenic but not protective in a mouse model of P. carinii pneumonia.

Authors:  F Gigliotti; J A Wiley; A G Harmsen
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

8.  Reduction of pulmonary surfactant in patients with human immunodeficiency virus infection and Pneumocystis carinii pneumonia.

Authors:  A G Hoffman; M G Lawrence; F P Ognibene; A F Suffredini; G Y Lipschik; J A Kovacs; H Masur; J H Shelhamer
Journal:  Chest       Date:  1992-12       Impact factor: 9.410

9.  Properties of the major antigens of rat and human Pneumocystis carinii.

Authors:  M J Linke; M T Cushion; P D Walzer
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

10.  The interaction in vitro of Pneumocystis carinii with macrophages and L-cells.

Authors:  H Masur; T C Jones
Journal:  J Exp Med       Date:  1978-01-01       Impact factor: 14.307
View more
  14 in total

1.  Seroepidemiological study of Pneumocystis jirovecii infection in healthy infants in Chile using recombinant fragments of the P. jirovecii major surface glycoprotein.

Authors:  Kpandja Djawe; Kieran R Daly; Sergio L Vargas; M Elena Santolaya; Carolina A Ponce; Rebeca Bustamante; Judith Koch; Linda Levin; Peter D Walzer
Journal:  Int J Infect Dis       Date:  2010-12       Impact factor: 3.623

2.  CD8 T cells modulate CD4 T-cell and eosinophil-mediated pulmonary pathology in pneumocystis pneumonia in B-cell-deficient mice.

Authors:  Steve D Swain; Nicole N Meissner; Allen G Harmsen
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

3.  Human immunodeficiency virus-infected patients with prior Pneumocystis pneumonia exhibit increased serologic reactivity to several major surface glycoprotein clones.

Authors:  K R Daly; J V Koch; N J Shire; L Levin; P D Walzer
Journal:  Clin Vaccine Immunol       Date:  2006-10

Review 4.  The ecology of pneumocystis: perspectives, personal recollections, and future research opportunities.

Authors:  Peter D Walzer
Journal:  J Eukaryot Microbiol       Date:  2013-09-03       Impact factor: 3.346

5.  Evidence for high prevalence of Pneumocystis jirovecii exposure among Cameroonians.

Authors:  Stephenson W Nkinin; Kieran R Daly; Peter D Walzer; Edward S Ndzi; Tazoacha Asonganyi; Nieves Respaldiza; Francisco J Medrano; Edna S Kaneshiro
Journal:  Acta Trop       Date:  2009-08-07       Impact factor: 3.112

6.  Neither neutrophils nor reactive oxygen species contribute to tissue damage during Pneumocystis pneumonia in mice.

Authors:  Steve D Swain; Terry W Wright; Peter M Degel; Francis Gigliotti; Allen G Harmsen
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

7.  Absence of the macrophage mannose receptor in mice does not increase susceptibility to Pneumocystis carinii infection in vivo.

Authors:  Steve D Swain; Sena J Lee; Michel C Nussenzweig; Allen G Harmsen
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

8.  Pneumocystis colonization in immunocompetent and simian immunodeficiency virus-infected cynomolgus macaques.

Authors:  Heather M Kling; Timothy W Shipley; Sangita Patil; Alison Morris; Karen A Norris
Journal:  J Infect Dis       Date:  2009-01-01       Impact factor: 5.226

9.  Geographical variation in serological responses to recombinant Pneumocystis jirovecii major surface glycoprotein antigens.

Authors:  K Daly; J Koch; N Respaldiza; C de la Horra; M A Montes-Cano; F J Medrano; J M Varela; E J Calderon; P D Walzer
Journal:  Clin Microbiol Infect       Date:  2009-03-21       Impact factor: 8.067

10.  Serologic responses to recombinant Pneumocystis jirovecii major surface glycoprotein among Ugandan patients with respiratory symptoms.

Authors:  Robert J Blount; Leah G Jarlsberg; Kieran R Daly; William Worodria; J Lucian Davis; Adithya Cattamanchi; Kpandja Djawe; Alfred Andama; Judith Koch; Peter D Walzer; Laurence Huang
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.